



Case Study: Noxopharm leverages Automatic's EFT payment capability for IPO applications to successfully list on the ASX.

Who are Noxopharm Limited?

Noxopharm is an Australian drug development company with offices in Melbourne and Sydney. The Company has a primary focus on the development of drugs that address the problem of chemotherapy and radiotherapy resistance in cancer cells, the major hurdle facing improved survival prospects for cancer patients.

What were they trying to achieve?

Noxopharm sought to raise \$6 million via an initial public offering (IPO) and then following this, list on the ASX.

Rather than relying on the traditional cheque-based payment method, Noxopharm wanted to deliver an online

solution that would allow for a more efficient payment system for investors. Noxopharm wanted to avoid manual processes and reconciliations which are time consuming, costly and prone to error. Ultimately Noxopharm were striving to make this IPO process a positive experience for investors from the outset.

How did they do it?

After completing a thorough due-diligence process, Noxopharm engaged Automatic as their share registry provider. Automatic is an industry leader in technology and provided a simple, user friendly Electronic Funds Transfer (EFT) solution. This ensured payments were processed in a timely, automated and accurate manner.

The Automatic EFT solution provided investors with a unique, system-generated

Case Study: Noxopharm

12-digit reference number for inclusion in their EFT payment reference field. This allowed for the Automic system to auto-reconcile such payments in the IPO trust bank account to the IPO applications working class.

What was the outcome?

The IPO was strongly supported by existing and new investors and was oversubscribed. Sixty percent of payments were received by EFT from Noxopharm applicants.

Updates on the amount of funds raised and number of matched applications were provided in real-time to Noxopharm management and their advisors. This reduced unnecessary calls to query the status of the IPO, saving considerable time and money.

Shares were allotted and Noxopharm commenced trading on the ASX in August 2016.

Noxopharm went on to becoming the fifth most successful float for 2016, published in the Australian Financial Review on December 22, 2016 as having a 143% increase in its stock price, relative to its issue price of 20 cents.

Further Information

For more information, call your relationship manager or visit <http://automic.com.au> to get in touch.



Graham Kelly – Managing Director and Chief Executive Officer



“Ann, your professional approach during such an important time for us, and during what has been at times challenging, has not gone un-noticed.

You have been patient and informative and we have really appreciated your advice and help.

The over-riding thought for me is “We had a great Share Registry and a fabulous Share Register Manager”.

Prue Kelly, Executive Assistant and Investor Relations Manager, Noxopharm Limited